- Home
- CUE vs ANL Comparison
CUE vs ANL Comparison
Compare CUE & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- ANL
- Stock Information
- Founded
- CUE 2014
- ANL 2004
- Country
- CUE United States
- ANL Cayman Islands
- Employees
- CUE N/A
- ANL N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- ANL
- Sector
- CUE Health Care
- ANL
- Exchange
- CUE Nasdaq
- ANL Nasdaq
- Market Cap
- CUE 59.5M
- ANL 62.4M
- IPO Year
- CUE 2018
- ANL 2023
- Fundamental
- Price
- CUE $0.83
- ANL $1.68
- Analyst Decision
- CUE Strong Buy
- ANL Hold
- Analyst Count
- CUE 2
- ANL 1
- Target Price
- CUE $3.00
- ANL N/A
- AVG Volume (30 Days)
- CUE 118.2K
- ANL 9.0K
- Earning Date
- CUE 08-12-2025
- ANL 09-02-2025
- Dividend Yield
- CUE N/A
- ANL N/A
- EPS Growth
- CUE N/A
- ANL N/A
- EPS
- CUE N/A
- ANL N/A
- Revenue
- CUE $8,286,000.00
- ANL N/A
- Revenue This Year
- CUE N/A
- ANL N/A
- Revenue Next Year
- CUE $23.84
- ANL N/A
- P/E Ratio
- CUE N/A
- ANL N/A
- Revenue Growth
- CUE N/A
- ANL N/A
- 52 Week Low
- CUE $0.45
- ANL $1.10
- 52 Week High
- CUE $1.99
- ANL $3.89
- Technical
- Relative Strength Index (RSI)
- CUE 53.58
- ANL 55.77
- Support Level
- CUE $0.77
- ANL $1.50
- Resistance Level
- CUE $0.84
- ANL $1.99
- Average True Range (ATR)
- CUE 0.06
- ANL 0.15
- MACD
- CUE -0.00
- ANL 0.01
- Stochastic Oscillator
- CUE 71.90
- ANL 43.82
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.